(Q54289542)

27 May 2018

title

Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines (English)

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

28 November 2022

main subject

Neisseria gonorrhoeae

0 references

0 references

1 reference

8

C. C. Knapp

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1797455

28 November 2022

5

M. A. Pfaller

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1797455

28 November 2022

6

J. A. Washington

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1797455

28 November 2022

2

E. H. Gerlach

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1797455

28 November 2022

7

M. E. Erwin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1797455

28 November 2022

author name string

R. N. Jones

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1797455

28 November 2022

F. P. Koontz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1797455

28 November 2022

P. R. Murray

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1797455

28 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1797455

28 November 2022

publication date

1 September 1991

1 reference

27 May 2018

full work available at URL

https://api.elsevier.com/content/article/PII:073288939190065N?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

https://api.elsevier.com/content/article/PII:073288939190065N?httpAccept=text/plain

28 November 2022

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

Diagnostic Microbiology and Infectious Disease

28 November 2022

published in

1 reference

27 May 2018

volume

14

1 reference

27 May 2018

issue

5

1 reference

27 May 2018

page(s)

383-388

1 reference

27 May 2018

In vitro activity of difloxacin hydrochloride (A-56619), A-56620, and cefixime (CL 284,635; FK 027) against selected genital pathogens

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

1989 Sexually Transmitted Diseases Treatment Guidelines

28 November 2022

3

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

Comparative clinical efficacy of single oral doses of cefuroxime axetil and amoxicillin in uncomplicated gonococcal infections

28 November 2022

6

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

Cefuroxime axetil for treatment of uncomplicated gonorrhea

28 November 2022

7

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency

28 November 2022

8

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline

28 November 2022

9

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

Interpretive criteria, quality control guidelines, and drug stability studies for susceptibility testing of cefotaxime, cefoxitin, ceftazidime, and cefuroxime against Neisseria gonorrhoeae.

28 November 2022

10

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

One-shot treatment of uncomplicated gonorrhoea with third-generation cephalosporins with differing serum half-life. Results of a controlled trial with ceftriaxone and cefotaxime

28 November 2022

11

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

Efficacy and safety of a single 400 mg oral dose of cefixime in the treatment of uncomplicated gonorrhea

28 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men.

28 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin

28 November 2022

17

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

Single-dose cefuroxime axetil in the treatment of uncomplicated gonorrhea: a controlled trial

28 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against Neisseria gonorrhoeae

28 November 2022

20

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

Different doses of cefetamet pivoxil (Ro 15-8075) in the treatment of acute uncomplicated gonococcal urethritis in men

28 November 2022

22

1 reference

https://api.crossref.org/works/10.1016/0732-8893(91)90065-N

28 November 2022

Identifiers

1 reference

27 May 2018

1 reference

27 May 2018